文献速递乳腺癌

Giredestrant用于雌激素受体阳性、HER2阴性既往治疗过的晚期乳腺癌:随机II期acelERA乳腺癌研究结果

Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
PubMed 文献 · J Clin Oncol · 2024-03-27

acelERA BC研究比较giredestrant与医生选择的内分泌单药治疗用于雌激素受体阳性、HER2阴性晚期乳腺癌,主要终点研究者评估的无进展生存期风险比0.81(95%CI 0.60-1.10,P=0.1757),未达统计学显著;ESR1突变可评估患者中突变组风险比0.60(95%CI 0.35-1.03),无突变组0.88(95%CI 0.54-1.42)。耐受性良好,支持继续研究。

要点

  • 主要终点研究者评估无进展生存期风险比0.81(95%CI 0.60-1.10,P=0.1757),未达统计学显著。
  • ESR1突变可评估患者中,突变组风险比0.60(95%CI 0.35-1.03),无突变组0.88(95%CI 0.54-1.42)。
  • 治疗相关3-4级不良事件、严重不良事件及因不良事件停药在两组间均衡。

核心结论

  • acelERA BC研究主要终点研究者评估的无进展生存期未达统计学显著,但giredestrant在多数关键亚组中显示一致的治疗效应,ESR1突变肿瘤患者有获益趋势。
  • giredestrant耐受性良好,安全性特征与医生选择的内分泌单药治疗相当,与已知内分泌治疗风险一致。
  • 这些数据支持在其他研究中继续评估giredestrant。

研究设计与样本

  • II期acelERA BC研究(ClinicalTrials.gov标识符NCT04576455),随机对照设计。
  • 纳入绝经后、绝经前、围绝经期女性或男性,年龄18岁及以上,具有可测量病灶或可评估骨病灶,在1-2线系统治疗后疾病进展(≤1种靶向治疗、≤1种化疗方案,允许既往氟维司群)。
  • 按1:1随机分配至giredestrant 30 mg口服每日一次或根据当地指南选择氟维司群/芳香化酶抑制剂(绝经前女性和男性加黄体生成素释放激素激动剂),直至疾病进展或不可接受的毒性。
  • 分层因素为内脏 versus 非内脏疾病、既往细胞周期蛋白依赖性激酶4/6抑制剂、既往氟维司群。
  • 主要终点为研究者评估的无进展生存期。

主要发现

  • 临床截止日期2022年2月18日,中位随访7.9个月,N=303,研究者评估的无进展生存期风险比0.81(95%CI 0.60-1.10;P=0.1757)。
  • 在循环肿瘤DNA可评估患者(n=232)中,ESR1突变可检测患者(n=90)的风险比为0.60(95%CI 0.35-1.03),未检测到ESR1突变患者(n=142)的风险比为0.88(95%CI 0.54-1.42)。
  • 治疗相关3-4级不良事件、严重不良事件及因不良事件停药在两组间均衡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor-positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455). METHODS: Post-/pre-/perimenopausal women, or men, age 18 years or older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines of systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly assigned 1:1 to giredestrant (30 mg oral once daily) or fulvestrant/aromatase inhibitor per local guidelines (+luteinizing hormone-releasing hormone agonist in pre-/perimenopausal women, and men) until disease progression/unacceptable toxicity. Stratification was by visceral versus nonvisceral disease, prior cyclin-dependent kinase 4/6 inhibitor, and prior fulvestrant. The primary end point was investigator-assessed progression-free survival (INV-PFS). RESULTS: At clinical cutoff (February 18, 2022; median follow-up: 7.9 months; N = 303), the INV-PFS hazard ratio (HR) was 0.81 (95% CI, 0.60 to 1.10; P = .1757). In the prespecified secondary end point analysis of INV-PFS by ESR1 mutation (m) status in circulating tumor DNA-evaluable patients (n = 232), the HR in patients with a detectable ESR1m (n = 90) was 0.60 (95% CI, 0.35 to 1.03) versus 0.88 (95% CI, 0.54 to 1.42) in patients with no ESR1m detected (n = 142). Related grade 3-4 adverse events (AEs), serious AEs, and discontinuations due to AEs were balanced across arms. CONCLUSION: Although the acelERA BC study did not reach statistical significance for its primary INV-PFS end point, there was a consistent treatment effect with giredestrant across most key subgroups and a trend toward favorable benefit among patients with ESR1-mutated tumors. Giredestrant was well tolerated, with a safety profile comparable to PCET and consistent with known endocrine therapy risks. Overall, these data support the continued investigation of giredestrant in other studies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Martín M, Lim E, Chavez-MacGregor M, et al. Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. J Clin Oncol. 2024. PMID: 38537155. doi:10.1200/JCO.23.01500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。